BEYOND WEIGHT LOSS: EMERGING EXTRA-METABOLIC APPLICATIONS OF GLP-1 RECEPTOR AGONISTS IN CARDIOVASCULAR, RENAL, NEUROLOGICAL AND INFLAMMATORY DISORDERS: A NARRATIVE REVIEW
Introduction. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) were originally developed as antidiabetic agents exploiting the incretin effect to achieve glucose-dependent insulin secretion. Over the past decade, evidence from large-scale cardiovascular outcome trials (CVOTs), mechanistic studies, and emerging cli...